Impact of the FDA Approval of CTL019 in ALL
Wednesday, August 30, 2017
Gail J. Roboz, M.D., a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, spoke to OncLive about the impact of the FDA approval of tisagenlecleucel (CTL019; Kymriah) in select pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL).